- Visibility 228 Views
- Downloads 255 Downloads
- Permissions
- DOI 10.18231/j.ijcap.v.12.i.3.5
-
CrossMark
Cardiac remodelling and regeneration: State of the science, translational pathways, and clinical outlook
- Author Details:
-
Shivam Dubey *
Shivam Dubey *
Cardiac remodelling—structural, cellular, and molecular changes that reshape the heart after stress or injury—drives heart failure progression. In contrast, cardiac regeneration refers to the replacement of lost myocardium with new, functional tissue. Adult human hearts exhibit very low baseline cardiomyocyte renewal (<1% per year), insufficient to recover from large injuries, so post-infarction “healing” usually culminates in non-contractile scar and adverse remodelling. Recent advances across single-cell/spatial omics, comparative biology (zebrafish, neonatal mouse), mechanobiology (Hippo–YAP), immunology, biomaterials, engineered tissues, gene/mRNA delivery, and extracellular vesicles (EVs) are reshaping the translational landscape. Meanwhile, guideline-directed medical therapies (e.g., ARNI, SGLT2 inhibitors) and devices can induce reverse remodelling, improving volumes and function but without true remuscularization. This review synthesizes mechanistic insights and late-breaking evidence, outlines therapeutic strategies moving from paracrine repair to bona fide remuscularization, and highlights key hurdles for durable, arrhythmia-safe regeneration in humans.
References
- World Health Organization. Global status report on noncommunicable diseases 2023. Geneva: WHO; 2023. Available on: https://www.who.int/news-room/fact- sheets/detail/noncommunicable-diseases (accessed on 20 th Aug 2025)
- Frangogiannis NG. Cardiac fibrosis: Cell biological mechanisms, molecular pathways and therapeutic opportunities. Mol Aspects Med. 2019 Feb;65:70-99. doi: 10.1016/j.mam.2018.07.001
[Google Scholar] Epub 2018 Aug 2. PMID: 30056242. - Cohn JN, Ferrari R, Sharpe N. Cardiac remodelling--concepts and clinical implications: a consensus paper from an international forum on cardiac remodelling. Behalf of an International Forum on Cardiac Remodelling. J Am Coll Cardiol. 2000;35(3):569-82
- Konstam MA, Patten RD, Thomas I, Ramahi T, La Bresh K, Goldman S, Lewis W, Gradman A, Self KS, Bittner V, Rand W, Kinan D, Smith JJ, Ford T, Segal R, Udelson JE. Effects of losartan and captopril on left ventricular volumes in elderly patients with heart failure: results of the ELITE ventricular function substudy. Am Heart J. 2000;139(6):1081-7.
- Bergmann O, Zdunek S, Felker A, Salehpour M, Alkass K, Bernard S, Sjostrom SL, Szewczykowska M, Jackowska T, Dos Remedios C, Malm T, Andrä M, Jashari R, Nyengaard JR, Possnert G, Jovinge S, Druid H, Frisén J. Dynamics of Cell Generation and Turnover in the Human Heart. Cell. 2015;161(7):1566-75.
- Garbern JC, Lee RT. Heart regeneration: 20 years of progress and renewed optimism. Dev Cell. 2022;57(4):424-39.
- Gemberling M, Karra R, Dickson AL, Poss KD. Nrg1 is an injury- induced cardiomyocyte mitogen for the endogenous heart regeneration program in zebrafish. Elife. 2015;4:e05871.
- Porrello ER, Mahmoud AI, Simpson E, Hill JA, Richardson JA, Olson EN. et al. Transient regenerative potential of the neonatal mouse heart. Science. 2011;331(6020):1078-80.
- Tucker NR, Chaffin M, Fleming SJ, Hall AW, Parsons VA, Bedi KC Jr, Akkad AD, Herndon CN, Arduini A, Papangeli I, Roselli C, Aguet F, Choi SH, Ardlie KG, Babadi M, Margulies KB, Stegmann CM, Ellinor PT. Transcriptional and Cellular Diversity of the Human Heart. Circulation. 2020;142(5):466-82.
- Heallen T, Morikawa Y, Leach J, Tao G, Willerson JT, Johnson R. et al. Hippo signalling impedes adult heart regeneration. Development. 2013;140(23):4683-90.
- Tominaga Y, Kawamura T, Ito E, Takeda M, Harada A, Torigata K, Sakaniwa R, Sawa Y, Miyagawa S. Pleiotropic effects of extracellular vesicles from induced pluripotent stem cell-derived cardiomyocytes on ischemic cardiomyopathy: A preclinical study. J Heart Lung Transplant. 2024;43(1):85-99.
- Li J, Liu L, Zhang J, Qu X, Kawamura T, Miyagawa S, Sawa Y. Engineered Tissue for Cardiac Regeneration: Current Status and Future Perspectives. Bioengineering (Basel). 2022 Oct 22;9(11):605.
- Carluccio E, Dini FL, Correale M, Dattilo G, Ciccarelli M, Vannuccini F. et al. Working Group on Heart Failure of the Italian Society of Cardiology. Effect of sacubitril/valsartan on cardiac remodelling compared with other renin-angiotensin system inhibitors: a difference-in-difference analysis of propensity-score matched samples. Clin Res Cardiol. 2024;113(6):856-65.
- Savage P, Watson C, Coburn J, Cox B, Shahmohammadi M, Grieve D, Dixon L. Impact of SGLT2 inhibition on markers of reverse cardiac remodelling in heart failure: Systematic review and meta- analysis. ESC Heart Fail. 2024;11(6):3636-48.
- Aurora AB, Porrello ER, Tan W, Mahmoud AI, Hill JA, Bassel- Duby R, Sadek HA, Olson EN. Macrophages are required for neonatal heart regeneration. J Clin Invest. 2014;124(3):1382-92.
- Kuppe C, Ramirez Flores RO, Li Z, Hayat S, Levinson RT, Liao X. et al. Spatial multi-omic map of human myocardial infarction. Nature. 2022 Aug;608(7924):766-77.
- Carluccio E, Dini FL, Correale M, Dattilo G, Ciccarelli M, Vannuccini F. et al. Working Group on Heart Failure of the Italian Society of Cardiology. Effect of sacubitril/valsartan on cardiac remodeling compared with other renin-angiotensin system inhibitors: a difference-in-difference analysis of propensity-score matched samples. Clin Res Cardiol. 2024;113(6):856-65.
- Almufleh A, Marbach J, Chih S, Stadnick E, Davies R, Liu P, Mielniczuk L. Ejection fraction improvement and reverse remodeling achieved with Sacubitril/Valsartan in heart failure with reduced ejection fraction patients. Am J Cardiovasc Dis. 2017;7(6):108-13.
- Carluccio E, Biagioli P, Reboldi G, Mengoni A, Lauciello R, Zuchi C, D'Addario S, Bardelli G, Ambrosio G. Left ventricular remodelling response to SGLT2 inhibitors in heart failure: an updated meta-analysis of randomized controlled studies. Cardiovasc Diabetol. 2023 Sep 2;22(1):235. doi: 10.1186/s12933-023-01970-w
[Google Scholar] PMID: 37660005; PMCID: PMC10475184. - D'Uva G, Aharonov A, Lauriola M, Kain D, Yahalom-Ronen Y, Carvalho S, Weisinger K, Bassat E, Rajchman D, Yifa O, Lysenko M, Konfino T, Hegesh J, Brenner O, Neeman M, Yarden Y, Leor J, Sarig R, Harvey RP, Tzahor E. ERBB2 triggers mammalian heart 116 Dubey / Indian Journal of Clinical Anatomy and Physiology 2025;12(3):107–117 regeneration by promoting cardiomyocyte dedifferentiation and proliferation. Nat Cell Biol. 2015;17(5):627-38.
- Chong JJ, Yang X, Don CW, Minami E, Liu YW, Weyers JJ. Et al. Human embryonic-stem-cell-derived cardiomyocytes regenerate non-human primate hearts. Nature. 2014;510(7504):273-7.
- Miyagawa S, Kainuma S, Kawamura T, Suzuki K, Ito Y, Iseoka H. et al. Case report: Transplantation of human induced pluripotent stem cell-derived cardiomyocyte patches for ischemic cardiomyopathy. Front Cardiovasc Med. 2022;9:950829.
- Osaka University (trial brief). Clinical trial on cardiomyocyte sheets made from iPS cells. 2020–ongoing. Available on: https://www.med.osaka-u.ac.jp/eng/archives/6393 (accessed on 19 th Aug 2025)
- Poss KD, Wilson LG, Keating MT. Heart regeneration in zebrafish. Science. 2002;298(5601):2188-90.
- González-Rosa JM, Burns CE, Burns CG. Zebrafish heart regeneration: 15 years of discoveries. Regeneration (Oxf). 2017;4(3):105-23.
- Zhao L, Ben-Yair R, Burns CE, Burns CG. Endocardial Notch Signaling Promotes Cardiomyocyte Proliferation in the Regenerating Zebrafish Heart through Wnt Pathway Antagonism. Cell Rep. 2019;26(3):546-554.e5
- Sánchez-Iranzo H, Galardi-Castilla M, Sanz-Morejón A, González- Rosa JM, Costa R, Ernst A. Transient fibrosis resolves via fibroblast inactivation in the regenerating zebrafish heart. Proc Natl Acad Sci U S A. 2018;115(16):4188-93.
- Cano-Martínez A, Vargas-González A, Guarner-Lans V, Prado- Zayago E, León-Oleda M, Nieto-Lima B. Functional and structural regeneration in the axolotl heart (Ambystoma mexicanum) after partial ventricular amputation. Arch Cardiol Mex. 2010;80(2):79-
- de Wit L, Fang J, Neef K, Xiao J, A Doevendans P, Schiffelers RM, Lei Z, Sluijter JPG. Cellular and Molecular Mechanism of Cardiac Regeneration: A Comparison of Newts, Zebrafish, and Mammals. Biomolecules. 2020;10(9):1204.
- Alkass K, Panula J, Westman M, Wu TD, Guerquin-Kern JL, Bergmann O. No Evidence for Cardiomyocyte Number Expansion in Preadolescent Mice. Cell. 2015;163(4):1026-36.
- Ye L, D'Agostino G, Loo SJ, Wang CX, Su LP, Tan SH. et al. Early Regenerative Capacity in the Porcine Heart. Circulation. 2018;138(24):2798-808.
- Lavine KJ, Epelman S, Uchida K, Weber KJ, Nichols CG, Schilling JD. et al. Distinct macrophage lineages contribute to disparate patterns of cardiac recovery and remodeling in the neonatal and adult heart. Proc Natl Acad Sci U S A. 2014;111(45):16029-34.
- Prajapati R, Qin T, Connelly KA, Merdad A, Chow CM, Leong-Poi H, Ong G. Echocardiographic Assessment of Cardiac Remodeling According to Obesity Class. Am J Cardiol. 2025;236:34-41.
- Zhu C, Yuan T, Krishnan J. Targeting cardiomyocyte cell cycle regulation in heart failure. Basic Res Cardiol. 2024;119(3):349-69.
- Talman V, Ruskoaho H. Cardiac fibrosis in myocardial infarction- from repair and remodeling to regeneration. Cell Tissue Res. 2016;365(3):563-81.
- Zambrano MA, Alcaide P. Immune Cells in Cardiac Injury Repair and Remodeling. Curr Cardiol Rep. 2023;25(5):315-23.
- Menasche P. Cardiac cell therapy: lessons from clinical trials. J Mol Cell Cardiol. 2011 Feb;50(2):258-65.
- Madonna R, Van Laake LW, Davidson SM, Engel FB, Hausenloy DJ, Lecour S. et al. Position Paper of the European Society of Cardiology Working Group Cellular Biology of the Heart: cell- based therapies for myocardial repair and regeneration in ischemic heart disease and heart failure. Eur Heart J. 2016;37(23):1789-98.
- Rayat Pisheh H, Nojabaei FS, Darvishi A, Rayat Pisheh A, Sani M. Cardiac tissue engineering: an emerging approach to the treatment of heart failure. Front Bioeng Biotechnol. 2024;12:1441933.
- Zangi L, Lui KO, von Gise A, Ma Q, Ebina W, Ptaszek LM.et al. Modified mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction. Nat Biotechnol. 2013;31(10):898-907.
- Qian L, Srivastava D. Direct cardiac reprogramming: from developmental biology to cardiac regeneration. Circ Res. 2013;113(7):915-21.
- Shiba Y, Gomibuchi T, Seto T, Wada Y, Ichimura H, Tanaka Y. et al. Allogeneic transplantation of iPS cell-derived cardiomyocytes regenerates primate hearts. Nature. 2016;538(7625):388-391.
- Kim J, Nam Y, Jeon D, Choi Y, Choi S, Hong CP, Kim S, Jung H, Park N, Sohn Y, Rim YA, Ju JH. Generation of hypoimmunogenic universal iPS cells through HLA-type gene knockout. Exp Mol Med. 2025;57(3):686-99.
- Axelle B, Grandela, Catarina & Gallant, James & Mummery, Christine & Menasché, Philipp. Revitalizing the heart: strategies and tools for cardiomyocyte regeneration post- myocardial infarction Check for updates. Regenerative Medicine. 2025;10.
- Burridge PW, Sharma A, Wu JC. Genetic and Epigenetic Regulation of Human Cardiac Reprogramming and Differentiation in Regenerative Medicine. Annu Rev Genet. 2015;49:461-84.
- Wu CA, Zhu Y, Woo YJ. Advances in 3D Bioprinting: Techniques, Applications, and Future Directions for Cardiac Tissue Engineering. Bioengineering (Basel). 2023;10(7):842.
- Vunjak-Novakovic G, Ronaldson-Bouchard K, Radisic M. Organs- on-a-chip models for biological research. Cell. 2021;184(18):4597-
- Lewis-Israeli YR, Volmert BD, Gabalski MA, Huang AR, Aguirre A. Generating Self-Assembling Human Heart Organoids Derived from Pluripotent Stem Cells. J Vis Exp. 2021;(175):10.3791/63097
[Google Scholar] - Stehlik J, Schmalfuss C, Bozkurt B, Nativi-Nicolau J, Wohlfahrt P, Wegerich S. Continuous Wearable Monitoring Analytics Predict Heart Failure Hospitalization: The LINK-HF Multicenter Study. Circ Heart Fail. 2020;13(3):e006513.
- Sopic M, Robinson EL, Emanueli C, Srivastava P, Angione C, Gaetano C, Condorelli G, Martelli F, Pedrazzini T, Devaux Y; EU- CardioRNA COST Action CA17129 and EU-AtheroNET COST Action CA21153. Integration of epigenetic regulatory mechanisms in heart failure. Basic Res Cardiol. 2023;118(1):16.
- de Kanter AJ, Jongsma KR, Verhaar MC, Bredenoord AL. The Ethical Implications of Tissue Engineering for Regenerative Purposes: A Systematic Review. Tissue Eng Part B Rev. 2023;29(2):167-87.
- Menasché P, Vanneaux V, Hagège A, Bel A, Cholley B, Parouchev A. Transplantation of Human Embryonic Stem Cell-Derived Cardiovascular Progenitors for Severe Ischemic Left Ventricular Dysfunction. J Am Coll Cardiol. 2018;71(4):429-38.
- Di Baldassarre A, Cimetta E, Bollini S, Gaggi G, Ghinassi B. Human-Induced Pluripotent Stem Cell Technology and Cardiomyocyte Generation: Progress and Clinical Applications. Cells. 2018;7(6):48.
- Blum B, Benvenisty N. The tumorigenicity of human embryonic stem cells. Adv Cancer Res. 2008;100:133-58.
- Zhao T, Zhang ZN, Rong Z, Xu Y. Immunogenicity of induced pluripotent stem cells. Nature. 2011;474(7350):212-5.
- Mingozzi F, High KA. Immune responses to AAV vectors: overcoming barriers to successful gene therapy. Blood. 2013;122(1):23-36
- Frangogiannis NG. Pathophysiology of Myocardial Infarction. Compr Physiol. 2015;5(4):1841-75.
- Sahoo S, Losordo DW. Exosomes and cardiac repair after myocardial infarction. Circ Res. 2014;114(2):333-44.
- Wollert KC, Drexler H. Cell therapy for the treatment of coronary heart disease: a critical appraisal. Nat Rev Cardiol. 2010;7(4):204-
- Gyöngyösi M, Wojakowski W, Lemarchand P, Lunde K, Tendera M, Bartunek J. ACCRUE Investigators. Meta-Analysis of Cell-based CaRdiac stUdiEs (ACCRUE) in patients with acute myocardial infarction based on individual patient data. Circ Res. 2015;116(8):1346-60.
- Lecour S, Botker HE, Condorelli G, Davidson SM, Garcia-Dorado D, Engel FB. ESC working group cellular biology of the heart: position paper: improving the preclinical assessment of novel cardioprotective therapies. Cardiovasc Res. 2014;104(3):399-411. 117 Dubey / Indian Journal of Clinical Anatomy and Physiology 2025;12(3):107–117
- Ibanez B, Aletras AH, Arai AE, Arheden H, Bax J, Berry C. et al. Cardiac MRI Endpoints in Myocardial Infarction Experimental and Clinical Trials: JACC Scientific Expert Panel. J Am Coll Cardiol. 2019;74(2):238-56.
- Bartunek J, Davison B, Sherman W, Povsic T, Henry TD, Gersh B, Metra M, Filippatos G, Hajjar R, Behfar A, Homsy C, Cotter G, Wijns W, Tendera M, Terzic A. Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-1) trial design. Eur J Heart Fail. 2016;18(2):160-8.
- Berry DA. Adaptive clinical trials: the promise and the caution. J Clin Oncol. 2011;29(6):606-9.
- High KA, Roncarolo MG. Gene Therapy. N Engl J Med. 2019;381(5):455-64.
- Weinberger M, Riley PR. Animal models to study cardiac regeneration. Nat Rev Cardiol. 2024;21(2):89-105.
- Karakikes I, Ameen M, Termglinchan V, Wu JC. Human induced pluripotent stem cell-derived cardiomyocytes: insights into molecular, cellular, and functional phenotypes. Circ Res. 2015;117(1):80-8.
- de Wit L, Fang J, Neef K, Xiao J, A Doevendans P, Schiffelers RM, Lei Z, Sluijter JPG. Cellular and Molecular Mechanism of Cardiac Regeneration: A Comparison of Newts, Zebrafish, and Mammals. Biomolecules. 2020;10(9):1204.
- Kir D, Patel MJ, Munagala What Is the Status of Regenerative Therapy in Heart Failure? Curr Cardiol Rep.MR. 2021;23(10):146.
- Vagnozzi RJ, Maillet M, Sargent MA, Khalil H, Johansen AKZ. DeLeon-Pennell KY. Clinical translation of engineered heart tissue and extracellular vesicle therapy. Circulation, 2023;147(5), 357–70.